

## **Result Update**

#### Stock Details

Market cap (Rs mn)	:	14363
52-wk Hi/Lo (Rs)	:	190 / 95
Face Value (Rs)	:	2
3M Avg. daily vol (Nos)	:	309,575
Shares o/s (mn)	:	122
Source:Bloomberg		

#### **Financial Summary**

Y/E Mar (Rs mn)	FY18	FY19E	FY20E
Revenue	11,661	13,291	14,963
Growth (%)	(12.9)	14.0	12.6
EBITDA	1,944	2,241	2,582
EBITDA margin (%)	16.7	16.9	17.3
PAT	1,246	1,335	1,595
EPS	10.2	10.9	13.0
EPS Growth (%)	(6.3)	7.1	19.5
BV (Rs/share)	57	67	79
Dividend/share (Rs)	0.8	0.8	0.8
ROE (%)	17.9	16.3	16.9
ROCE (%)	12.0	12.0	12.9
P/E (x)	11.6	10.8	9.0
EV/EBITDA (x)	8.3	6.8	5.8
P/BV (x)	2.1	1.8	1.5

Source: Company, Kotak Securities - PCG

#### **Shareholding Pattern (%)**


(%)	Sep-18	Jun-18	Mar-18
Promoters	55.7	55.7	54.9
FII	6.5	6.2	7.4
DII	6.4	6.5	6.7
Others	31.4	31.6	31.0

Source: Company

#### Price Performance (%)

(%)	1M	3M	6M
Bodal Chemicals	10.2	(7.0)	(0.9)
Nifty	(8.5)	(9.0)	(4.2)
a a' i			

Source: Bloomberg



#### Jatin Damania

jatin.damania@kotak.com +91 22 6218 6440

## **BODAL CHEMICALS LTD**

## PRICE Rs.119

## TARGET RS.130

## ACCUMULATE

Bodal Chemicals Q2FY19 numbers were in line with estimates. EBITDA margin during the quarter strengthened further by 40bps QoQ, supported by a change in product mix and a higher realisation. Going ahead, we foresee contribution from new dyestuff capacity to support revenue growth.

## Key Highlights

- SPS performance improved sequentially and reported Rs305 mn of revenue and PAT of Rs16 mn (supported by increased in volume and a higher realisation), while Trion Chemicals continues with its weak performance and recovery to take some more time. Trion reported loss of Rs25mn in 2QFY19.
- Dyestuff Phase I expansion of 12,000 tonnes operated at 65% utilisation.
- □ The company market shares stands at 25% in domestic and 6% in global dye intermediates industry and 9% in domestic and 3% in global dyestuff industry.
- Dye intermediates realisation declined by 6-7% from the average in 2QFY19 starting October due to low demand. Second half is seasonally weak for the industry.

## Valuation & outlook

Given the future road map in terms of revenue visibility and margin expansion plans in place by undertaking an aggressive capex plan, we believe that long term story still remains intact. In the near term, the recent uptick in intermediate prices (compared to FY18) and contribution for Dyestuff expansion shall support the earnings, but a weak performance from Trion chemicals would partly offset the benefit. The stock at current valuations of 10.8x/9.0x FY19E/FY20E earnings, factors in all the potential negatives. But re-rating will take some more time. Recommend **ACCUMULATE** (earlier Reduce) with an unchanged target price Rs130.

#### Quarterly performance table

Particulars (Rs Mn)	2QFY19	2QFY18	% <b>YoY</b>	1QFY19	% <b>QoQ</b>
Net Sales	3,932	2,561	53.5	3,517	11.8
Raw Materials	2,339	1,522	53.7	2,118	10.4
% to sales	59.5	59.4		60.2	
Employee Costs	171	107	59.9	159	7.6
% to sales	4.3	4.2		4.5	
Total Expenditures	3,204	2,100	52.5	2,879	11.3
EBITDA	728	461	58.1	638	14.2
EBITDA Margin	18.5	18.0		18.1	
Depreciation	54	73	(26.1)	46	18.2
EBIT	675	388	73.9	592	13.9
Interest	20	9	119.2	16	24.8
Other Income	30	14	123.5	24	26.6
РВТ	685	392	74.5	600	14.1
Tax	234	137	71.1	207	13.4
PAT	450	255	76.3	393	14.5
Share of Asso	0	(7)		(9)	
PAT	450	248	81.6	384	17.2

Source: Company, Kotak Securities – Private Client Research



# Higher volume, better realisation and increased share of export boost the performance

During the quarter, the company reported highest ever quarterly production, with dye stuff production up by 54% YoY supported by the new facility. Dye intermediates production was up by 11.6% and basic chemicals registered production growth of 15.3%. This, coupled with a better realisation in dye intermediates and increase in export share to 47% (43% in 1QFY19), helped the company to report 53.5%/11.8% YoY/QoQ growth in revenue to Rs3.93 bn. Export revenue during the quarter stood at Rs1.73 bn. Viny Sulphone and H-Acid realisation stood at Rs278/kg and Rs451/kg, respectively. Current prices of both these intermediates are 6-7% lower than the average of 2QFY19.

Higher export sales, coupled with increased captive consumption of dye intermediates offset the impact of increased raw materials and employee cost and led to 58.1%/14.2% YoY/QoQ jump in EBITDA to Rs728mn, with an EBITDA margin of 18.5%. Basic chemical share in overall product basket declined to 10% from 12% in 2QFY19, on the other hand, high value product such as Dye intermediates and dye stuff, share increased from 46% and 29% in 1QFY19 to 49.5% and 35.4%, respectively. Strong operating performance resulted into 81.6%/17.2% YoY/QoQ growth in PAT to Rs450 mn.

Management expects the margin to remain in the range of 18-19%. But, we believe that, the increase in the raw material can act a key headwind in the coming months and seasonally second half is weak in terms of volume and realisation. Hence, we expect margin to be in the range of 16-17.5%.

#### **Operational Performance**

Production	Q2FY19	Q2FY18	% YoY	Q1FY19	% <b>QoQ</b>
Dye Intermediates	6,031	5,403	11.6	6,217	(3.0)
Dyestuff	5,277	3,420	54.3	4,358	21.1
Basic Chemicals	51,522	44,672	15.3	50,448	2.1

Source: Company

#### Revenue Break-up (Rs Mn)

Product	Q2FY19	Q2FY18	% YoY	Q1FY19	% <b>QoQ</b>
Dye Intermediates	1,822	1,482	22.9	1,690	7.8
Dyestuff	1,301	751	73.2	1,078	20.7
Basic Chemicals	379	208	82.2	476	(20.4)
Others	176	157	12.1	237	(25.7)

Source: Company

#### **Domestic vs Export**

Particulars	Q2FY19	Q2FY18	% YoY	Q1FY19	% <b>QoQ</b>
Domestic	1,950	1,979	(1.5)	1,968	(0.9)
Export	1,730	619	179.5	1,513	14.3

Source: Company



# Current valuation factors potential negatives; recommend ACCUMULATE

Given the future road map in terms of revenue visibility and margin expansion plans in place, by undertaking an aggressive capex plan, we believe that long term story still remains intact. In the near term, the recent uptick in intermediate prices and contribution for Dyestuff phase I expansion shall support the earnings, but a weak performance from Trion chemicals would partly offset the benefit. The stock at current valuations of 10.8x/9.0x FY19E/FY20E earnings, factors in all the potential negatives.

## **Other Highlights:**

- Trion Chemicals: The company has started production at Trion, as raw material prices have softened (but still at a higher level). The management expects Trion to achieve break-even by end of FY19E. The company has increased its stake in Trion to 59% from 52%.
- **SPS:** The jump in revenue at SPS was driven by higher H-Acid realisation during the quarter. VS facility is yet to commence operation

**Dyestuff expansion:** Considering the sharp increase achieved in recently added Dyestuff capacity during the quarter, the company decided to further expand dyestuff (powder) capacity by 6000 MTPA, ahead of original schedule, at Unit-7, at an estimated cost of Rs.260 mn. Management expect the new facility to come on stream by 1QFY20. Post the completion of the expansion, total Dyestuff capacity (powder) of the company will be 35000 MTPA.

During H1FY19, company has made capex of Rs. 743 mn including capital work in progress which includes Thionyl Chloride, new office building, and storage & infrastructure facility for Dyestuff, Land & maintenance capex. Total capex for FY19 stands at Rs1.2 bn.

The company is planning to setup a subsidiary for trading business in India for exports as well as to cater the requirements of the domestic market. The company is also looking to setup subsidiary in Bangladesh and Turkey.

## **Company Background**

Bodal Chemicals Limited is integrated company, offering end-to-end solution to our customers globally. The company is among world's largest manufacturer and exporter of Dyes Intermediate, Dyestuff and Sulphuric Acid, with vertically and horizontally integrated who provides product solutions and service solution on fastest possible route to their customers. BCL having its presence not only in India but across the globe and serving to 50+ countries with its Innovative products and services. BCL with presence across dyestuff value chain and strong domestic/exports penetration is aptly placed to take benefit of opportunities in dyestuff industry.

## **Financials: Consolidated**

## Profit and Loss Statement (Rs mn)

(Year-end Mar)	FY17	FY18	FY19E	FY20E
Net sales	13,392	11,661	13,291	14,963
growth (%)	47.2	(12.9)	14.0	12.6
Operating expenses	11,132	9,718	11,050	12,381
EBITDA	2,260	1,944	2,241	2,582
growth (%)	50.9	(14.0)	15.3	15.2
Depreciation & amortisation	289	121	174	235
EBIT	1,972	1,823	2,066	2,347
Other income	105	95	49	54
Interest paid	87	53	69	56
Exceptional items	49	0	0	0
PBT	2,038	1,865	2,046	2,345
Тах	709	619	675	715
Effective tax rate (%)	34.8	33.2	33.0	30.5
Net profit	1,329	1,246	1,371	1,631
Share of Asso.	(0)	0	36	36
Reported Net profit	1,329	1,246	1,335	1,595
growth (%)	54.6	(6.3)	7.1	19.5

Source: Company, Kotak Securities – Private Client Research

#### Cash flow Statement (Rs mn)

(Year-end Mar)	FY17	FY18	FY19E	FY20E
Pre-tax profit	2,038	1,865	2,046	2,167
Depreciation	289	121	174	235
Chg in working capital	(448)	(902)	1,135	(209)
Total tax paid	698	619	675	715
Other operating activities	(12)	53	69	56
Operating CF	1,169	518	2,750	1,533
Capital expenditure	(531)	(1,044)	(1,685)	(1,056)
Chg in investments	(00.1)	(44)	0	0
Other investing activities	(236)	0 0	0	0
Investing CF	(767)	(1,088)	(1,685)	(1,056)
Equity raised/(repaid)	0	2,224	0	0
Debt raised/(repaid)	(101)	308	(629)	(250)
Dividend (incl. tax)	(40)	(114)	(114)	(114)
Other financing activities	(87)	(53)	(69)	(56)
Financing CF	(228)	2,364	(813)	(420)
Net chg in cash & bank bal.	174	1,795	252	56
Closing cash & bank bal	167	59	311	296

Source: Company, Kotak Securities – Private Client Research



## Balancesheet(Rsmn)

(Year-end Mar)	FY17	FY18	FY19E	FY20E
Cash & Bank balances	167	59	311	296
Other Current assets	4,366	5,672	4,654	5,064
Investments	125	169	169	169
Net fixed assets	2,306	4,553	6,063	6,884
Other non-current assets	10	264	264	264
Total assets	6,975	10,717	11,461	12,678
Current liabilities	1,686	1,684	1,801	2,002
Borrowings	1,490	1,808	1,179	929
Other non-current liabilities	190	244	244	244
Total liabilities	3,365	3,736	3,224	3,175
Share capital	218	218	218	218
Reserves & surplus	3,374	6,751	7,971	9,201
Shareholders' funds	3,593	6,969	8,190	9,419
Minority interest	18	11	47	83
Total equity & liabilities	6,975	10,716	11,461	12,678

Source: Company, Kotak Securities – Private Client Research

#### **Ratio Analysis**

(Year-end Mar)	FY17	FY18	FY19E	FY20E
Profitability and return	ratios (%)			
EBITDAM	16.9	16.7	16.9	17.3
EBITM	14.7	15.6	15.5	15.7
NPM	9.6	10.7	10.0	10.7
RoE	35.6	17.9	16.3	16.9
RoCE	19.2	12.0	12.0	12.9
Per share data (Rs)				
EPS	11.7	10.2	10.9	13.0
FDEPS	11.7	10.2	10.9	13.0
CEPS	14.4	11.2	12.3	15.0
BV	31.4	57.0	67.0	79.0
DPS	0.3	0.8	0.8	0.8
Valuation ratios (x)				
PE	10.1	11.6	10.8	9.0
P/BV	3.8	2.1	1.8	1.5
EV/EBITDA	6.3	8.3	6.8	5.8
EV/Sales	1.1	1.4	1.2	1.0
Other key ratios				
D/E (x)	0.4	0.3	0.1	0.1
Debtors Days	54	90	90	90

Source: Company, Kotak Securities – Private Client Research



### **RATING SCALE**

Definitions of ratings		
BUY	_	We expect the stock to deliver more than 12% returns over the next 12 months
ACCUMULATE	_	We expect the stock to deliver 5% - 12% returns over the next 12 months
REDUCE	-	We expect the stock to deliver 0% - 5% returns over the next 12 months
SELL	_	We expect the stock to deliver negative returns over the next 12 months
NR	-	<b>Not Rated.</b> Kotak Securities is not assigning any rating or price target to the stock. The report has been prepared for information purposes only.
SUBSCRIBE	-	We advise investor to subscribe to the IPO.
RS	_	<b>Rating Suspended.</b> Kotak Securities has suspended the investment rating and price target for this stock, either because there is not a Sufficient fundamental basis for determining, or there are legal, regulatory or policy constraints around publishing, an investment rating or target. The previous investment rating and price target, if any, are no longer in effect for this stock and should not be relied upon.
NA	-	<b>Not Available or Not Applicable.</b> The information is not available for display or is not applicable
NM	_	Not Meaningful. The information is not meaningful and is therefore excluded.
NOTE	-	Our target prices are with a 12-month perspective. Returns stated in the rating scale are our internal benchmark.

## **FUNDAMENTAL RESEARCH TEAM**

Rusmik Oza Head of Research rusmik.oza@kotak.com +91 22 6218 6441

Sanjeev Zarbade Cap. Goods & Cons. Durables sanjeev.zarbade@kotak.com +91 22 6218 6424

Teena Virmani Construction, Cement, Buildg Mat Oil and Gas, Information Tech teena.virmani@kotak.com +91 22 6218 6432

K. Kathirvelu Support Executive k.kathirvelu@kotak.com +91 22 6218 6427

Arun Agarwal Auto & Auto Ancillarv arun.agarwal@kotak.com +91 22 6218 6443

**Ruchir Khare** Cap. Goods & Cons. Durables ruchir.khare@kotak.com +91 22 6218 6431

Sumit Pokharna sumit.pokharna@kotak.com +91 22 6218 6438

Amit Agarwal Transportation, Paints, FMCG agarwal.amit@kotak.com +91 22 6218 6439

Jatin Damania Metals & Mining, Midcap jatin.damania@kotak.com +91 22 6218 6440

Pankaj Kumar Midcap pankajr.kumar@kotak.com +91 22 6218 6434

Nipun Gupta Information Tech, Midcap nipun.gupta@kotak.com +91 22 6218 6433

Cyndrella Carvalho Pharmaceuticals cyndrella.carvalho@kotak.com +91 22 6218 6426

Jayesh Kumar Economist kumar.jayesh@kotak.com +91 22 6218 5373

Deval Shah Research Associate deval.shah@kotak.com +91 22 6218 6423

Ledo Padinjarathala **Research Associate** ledo.padinjarathala@kotak.com +91 22 6218 7021

Krishna Nain M&A, Corporate actions krishna.nain@kotak.com +91 22 6218 7907

## **TECHNICAL RESEARCH TEAM**

Shrikant Chouhan shrikant.chouhan@kotak.com +91 22 6218 5408

Amol Athawale amol.athawale@kotak.com +91 20 6620 3350

## **DERIVATIVES RESEARCH TEAM**

Sahaj Agrawal sahaj.agrawal@kotak.com +91 79 6607 2231

Malay Gandhi malay.gandhi@kotak.com +91 22 6218 6420

Prashanth Lalu prashanth.lalu@kotak.com +91 22 6218 5497

Prasenjit Biswas, CMT, CFTe prasenjit.biswas@kotak.com +91 33 6625 9810



#### **Disclosure/Disclaimer**

Kotak Securities Limited established in 1994, is a subsidiary of Kotak Mahindra Bank Limited. Kotak Securities is one of India's largest brokerage and distribution house. Kotak Securities Limited is a corporate trading and clearing member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), Metropolitan Stock Exchange of India Limited (MSE). Our businesses include stock broking, services rendered in connection with distribution of primary market issues and financial products like mutual funds and fixed deposits, depository services and Portfolio Management. Kotak Securities Limited is also a depository participant with National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL). Kotak

Securities Limited is also registered with Association of Mutual Funds in India (AMFI). We are registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014,

We hereby declare that our activities were neither suspended nor we have defaulted with any stock exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advise/warning/deficiency letters/ or levied minor penalty on KSL for certain operational deviations. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time.

We offer our research services to clients as well as our prospects.

This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions.

This material is for the personal information of the authorized recipient, and we are not soliciting any action based upon it. This report is not to be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It is for the general information of clients of Kotak Securities Ltd. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients.

We have reviewed the report, and in so far as it includes current or historical information, it is believed to be reliable though its accuracy or completeness cannot be guaranteed. Neither Kotak Securities Limited, nor any person connected with it, accepts any liability arising from the use of this document. The recipients of this material should rely on their own investigations and take their own professional advice. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions -including those involving futures, options and other derivatives as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

Opinions expressed are our current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forwardlooking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

Kotak Securities Limited has two independent equity research groups: Institutional Equities and Private Client Group. This report has been prepared by the Private Client For the views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Equities Research Group. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, target price of the Institutional Equities Research Group of Kotak Securities Limited.

We and our affiliates/associates, officers, directors, and employees, Research Analyst(including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company (ies) discussed herein or act as advisor or lender / borrower to such company (ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of Research Report or at the time of public appearance. Kotak Securities Limited (KSL) may have proprietary long/short position in the above mentioned scrip(s) and therefore may be considered as interested. The views provided herein are general in nature and does not consider risk appetite or investment objective of particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with KSL. Kotak Securities Limited is also a Portfolio Manager. Portfolio Management Team (PMS) takes its investment decisions independent of the PCG research and accordingly PMS may have positions contrary to the PCG research recommendation. Kotak Securities Limited does not provide any promise or assurance of favourable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing.

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report. No part of this material may be duplicated in any form and/or redistributed without Kotak Securities' prior written consent.

Details of Associates are available on www.kotak.com

Research Analyst has served as an officer, director or employee of subject company(ies): No We or our associates may have received compensation from the subject company(ies) in the past 12 months.

We or our associates have managed or co-managed public offering of securities for the subject company(ies) in the past 12 months: No

We or our associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months. We or our associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months. We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report. Our associates may have financial interest in the subject company(ies).

Research Analyst or his/her relative's financial interest in the subject company(ies): No

Kotak Securities Limited has financial interest in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No. Our associates may have actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.

Research Analyst or his/her relatives has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No.

Kotak Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No

By referring to any particular sector, Kotak Securities Limited does not provide any promise or assurance of favourable view for a particular industry or sector or business group in any manner. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and take professional advice before investing. Such representations are not indicative of future results.

Subject company(ies) may have been client during twelve months preceding the date of distribution of the research report.

"A graph of daily closing prices of securities is available at https://www.nseindia.com/ChartApp/install/charts/mainpage.jsp and

http://economictimes.indiatimes.com/markets/stocks/stock-quotes. (Choose a company from the list on the browser and select the "three years" icon in the price chart)."

Kotak Securities Limited. Registered Office: 27 BKC, C 27, G Block, Bandra Kurla Complex, Bandra (E), Mumbai 400051. CIN: U99999MH1994PLC134051, Telephone No.: +22 43360000, Fax No.: +22 67132430. Website: www.kotak.com/www.kotaksecurities.com. Correspondence Address: Infinity IT Park, Bldg. No 21, Opp. Film City Road, A K Vaidya Marg, Malad (East), Mumbai 400097. Telephone No: 42856825. SEBI Registration No: INZ000200137 (Member of NSE, BSE, MSE, MCX & NCDEX), AMFI ARN 0164, PMS INP000000258 and Research Analyst INH000000586. NSDL/CDSL: IN-DP-NSDL-23-97. Our research should not be considered as an advertisement or advice, professional or otherwise. The investor is requested to take into consideration all the risk factors including their financial condition, suitability to risk return profile and the like and take professional advice before investing. Investments in securities market are subject to market risks, read all the related documents carefully before investing. Derivatives are a sophisticated investment device. The investor is requested to take into consideration all the risk factors before actually trading in derivative contracts. Compliance Officer Details: Mr. Manoj Agarwal. Call: 022 - 4285 8484, or Email: ks.compliance@kotak.com.

In case you require any clarification or have any concern, kindly write to us at below email ids:

- Level 1: For Trading related queries, contact our customer service at 'service.securities@kotak.com' and for demat account related queries contact us at ks.demat@kotak.com or call us on: Toll free numbers 18002099191 / 1860 266 9191
- Level 2: If you do not receive a satisfactory response at Level 1 within 3 working days, you may write to us at ks.escalation@kotak.com or call us on 022-42858445 and if you feel you are still unheard, write to our customer service HOD at ks.servicehead@kotak.com or call us on 022-42858208.
- Level 3: If you still have not received a satisfactory response at Level 2 within 3 working days, you may contact our Compliance Officer (Mr. Manoj Agarwal) at ks.compliance@kotak.com or call on 91- (022) 4285 8484.
- Level 4: If you have not received a satisfactory response at Level 3 within 7 working days, you may also approach CEO (Mr. Kamlesh Rao) at ceo.ks@kotak.com or call on 91- (022) 4285 8301.